Testing a natural compound with chemo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial combines a natural substance called hydroxytyrosol (HT) with standard chemotherapy (5-FU and possibly other drugs) for people with advanced or metastatic colorectal cancer that hasn't been treated yet. The goal is to see if adding HT makes the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (spread) or metastatic colorectal cancer confirmed by a biopsy.
- You haven't had treatment for advanced cancer yet and are eligible for 5-FU chemotherapy.
- You are in generally good health (able to care for yourself and up and about at least half the day).
- You have at least one tumor that can be measured on scans.
- You are willing to use birth control if there is any chance of pregnancy.
- You don't have serious heart, liver, kidney, or bleeding problems, and you haven't had a recent heart attack or stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
This Phase 1 study tests TTX-080, a drug designed to block a cancer immune “signal” (HLA-G) to help the body fight advanced colorectal cancer. It mainly checks safety and how the treatment works in people with cancer that has spread.
Hear when a new Advanced or Metastatic CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.